Hello, everyone, and how are you this morning? We are doing just fine, thank you, now that the Pharmalot campus has quieted down. The short people have departed for their respective destinations — the local schoolhouse and gainful employment — which leaves us alone with the official mascots in our respective corners. All of which means the time has come to get cracking. On that note, here are a few items of interest to help you along. Hope you have a smashing day and do keep us in mind if anything interesting arises …

Novo Nordisk (NOV) will cut 400 R&D jobs from Denmark and China in order to shift investment toward “biological and technological innovation.” The drug maker, which employs more than 42,000 people globally, has encountered pricing pressures, especially on its key diabetes franchise in the U.S. “Our analysis shows that we have a surplus of manual labor and are lacking competences in the digital sphere, informatics, data science, artificial intelligence and automations,” Novo Nordisk chief science officer Mads Krogsgaard Thomsen tells Reuters.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy